News about Clinical Trials

Bayer Reports Positive Phase 3 Results for Investigational Cardiac Amyloidosis Imaging Agent

REVEAL study demonstrates strong diagnostic sensitivity and specificity of I 124 evuzamitide PET/CT radiotracer for detecting cardiac amyloidosis, supporting plans for regulatory discussions with the FDA.

Clinical Trials | 08/05/2026 | By News Bureau

Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27

The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.

Clinical Trials | 08/05/2026 | By News Bureau

Alebund Pharmaceuticals Completes Enrollment in Global Phase 3 Trial for AP301 Hyperphosphatemia Therapy

Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.

Clinical Trials | 07/05/2026 | By News Bureau

JNJ-4804 Co-Antibody Shows Promise in Refractory Inflammatory Bowel Disease

Johnson & Johnson (J&J) investigational JNJ-4804 co-antibody shows superior clinical and endoscopic outcomes in refractory Inflammatory Bowel Disease (IBD), supporting phase 3 advancement with dual IL-23 and TNF pathway targeting.

Clinical Trials | 07/05/2026 | By News Bureau

Anteris Technologies Global Corp. Begins US Enrollment in PARADIGM Trial for DurAVR Heart Valve

Anteris marks first patients successfully treated in US as global trial evaluates safety and effectiveness of DurAVR THV against existing transcatheter aortic valve therapies.

Clinical Trials | 06/05/2026 | By News Bureau

Altesa BioSciences Initiates Phase IIb CARDINAL Trial for COPD Treatment

Altesa BioSciences begins global CARDINAL trial to assess antiviral vapendavir for improving symptoms and lung function in COPD patients.

Clinical Trials | 06/05/2026 | By News Bureau

Eli Lilly and Company's Omvoh Shows 4-Year Disease Clearance in Ulcerative Colitis

Eli Lilly and Company’s Omvoh (mirikizumab-mrkz), the first IL-23p19 inhibitor, shows durable disease clearance in ulcerative colitis, with more than 60 percent of patients maintaining remission through 4 years in the LUCENT-3 study.

Clinical Trials | 06/05/2026 | By News Bureau

Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118

Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.

Clinical Trials | 05/05/2026 | By News Bureau

Ascidian Therapeutics Completes STELLAR Trial Dose Escalation for ACDN-01 in Stargardt Disease

Ascidian Therapeutics completes Phase 1/2 STELLAR dose escalation for ACDN-01 in Stargardt disease, advances pediatric enrollment, and launches STARPATH prescreening to accelerate clinical trial access.

Clinical Trials | 05/05/2026 | By News Bureau

Newron Pharmaceuticals Pauses US Enrollment in ENIGMA-TRS 2 Study

Newron Pharmaceuticals pauses enrolment at US sites in ENIGMA-TRS 2 study, while global ENIGMA-TRS 1 trial continues with more than 400 patients enrolled.

Clinical Trials | 02/05/2026 | By News Bureau